Here is a finding that sounds backwards until you look at it closely. In a nationwide study of 34,528 soft-tissue sarcoma patients, the ones who traveled farther for care tended to survive longer, and patients who traveled more than a hundred miles to an academic center had markedly better five-year survival than those who stayed close and were treated at non-academic hospitals. Travel, of course, is not medicine, and nobody lives longer for having sat in a car; the catch is entirely in where the travel led.
Close to home, only 37% of these patients were treated at an academic, specialist center, whereas among those who traveled more than a hundred miles, 75.9% were. The distance was not helping them. It was simply a marker for reaching the kind of center that helps, and that single insight reframes the entire distance problem, which is why it sits at the intellectual foundation of everything Beat the Odds does. The goal is never travel for its own sake but the destination the travel unlocks, the specialist center whose survival advantage we spent all of last week documenting. Distance is just the toll standing between many families and that destination.
Which raises the obvious and painful question: if reaching a specialist center changes the odds this much, why doesn’t everyone go? Because there are only about twenty such centers in the entire country, and getting to one costs money, gas, flights, hotels, and time off work, that most families do not have sitting in an account. The patients in that study who traveled far were, disproportionately, the ones who could afford to.
That is the inequity we exist to erase. The science could hardly be clearer that the destination matters, so the only variable left is whether a family can afford to reach it, and that, unlike the biology of a tumor, is a variable we can actually change. Distance should never be the thing that decides who gets the care that works.